By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is divided on HIMS' future, with concerns about margin compression from shifting to branded drugs and potential ARPU erosion, but also optimism about subscriber growth and long-term guidance.
Risk: Margin compression and ARPU erosion from shifting to branded drugs and potential product-mix issues.
Opportunity: Strong subscriber growth and long-term revenue guidance.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Hims & Hers missed horribly on earnings last night -- but raised sales guidance for the year.
Sales missed in Q1 as well, however.
Hims & Hers Health (NYSE: HIMS) stock tumbled 12% through 11:15 a.m. ET Tuesday after missing badly on Q1 earnings last night.
Heading into the report, analysts forecast the telehealth company, made famous for selling discount GLP-1 weight loss drugs (and getting sued repeatedly for it), would earn a tiny $0.01 per share profit on sales of $616.5 million. In fact, Hims & Hers lost $0.40 per share, and revenue was only $608 million.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Sales grew only 4% in the quarter, despite subscriber growth of 9%. (Which is to say, this may be a story of more consumers spending less money at Hims & Hers.)
Accentuating the positive, though, CEO Andrew Dudum insisted Hims & Hers is "not just growing, we're pulling away from the field on our path to becoming the world's largest consumer health platform." More than just adding customers, Hims & Hers is entering new markets, expanding into new drug categories, and focusing on "comprehensive diagnostics" to help differentiate itself as a provider of personalized healthcare.
At the same time, it's not abandoning the GLP-1 market at all. Rather than risk more lawsuits, Hims & Hers is focusing on reselling branded GLP-1 products from the major manufacturers, including Eli Lilly's (NYSE: LLY) Mounjaro and Zepbound and Novo Nordisk's (NYSE: NVO) Wegovy and Ozempic.
Turning to guidance, Hims & Hers expects all these efforts to pay off in the form of faster sales growth, projecting $2.8 billion to $3 billion by the end of this year and $6.5 billion in 2030 sales.
GAAP profits remain elusive, but Hims & Hers generated positive free cash flow of $53 million in the quarter -- putting it on course to generate perhaps $200 million this year.
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $460,826! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,345,285!
Now, it’s worth noting Stock Advisor’s total average return is 983% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 12, 2026. *
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"HIMS is facing a critical margin squeeze where subscriber growth is being outpaced by the rising costs of customer acquisition and lower-margin branded drug reselling."
The market is rightfully punishing HIMS for the disconnect between subscriber growth and revenue per user, which suggests a weakening pricing power or a shift toward lower-margin products. While management highlights a path to $6.5 billion in revenue by 2030, the $0.40 EPS miss reveals that the cost of customer acquisition (CAC) is ballooning, likely due to the intense marketing required to compete in the GLP-1 space. Moving to resell branded Eli Lilly and Novo Nordisk drugs is a defensive pivot that will compress margins compared to their proprietary compounding model. Until HIMS demonstrates that they can scale revenue without burning cash on aggressive marketing, the valuation remains speculative.
If HIMS successfully pivots to a 'platform' model, the $53 million in quarterly free cash flow proves they have the liquidity to outlast smaller telehealth competitors, potentially leading to a massive valuation re-rating once the marketing spend stabilizes.
"Raised FY guidance and FCF positivity trump the Q1 miss, positioning HIMS for re-rating as legal risks fade and platform expands."
HIMS stock's 12% drop looks like an overreaction to a Q1 EPS miss (-$0.40 vs. $0.01 est.) and revenue shortfall ($608M vs. $616.5M), especially with 9% subscriber growth outpacing 4% sales growth—hinting at temporarily softer ARPU (average revenue per user) from GLP-1 mix shift. Crucially, management raised FY24 sales guidance to $2.8B-$3B (from prior ~$2.5B implied) and projects $6.5B by 2030, while posting $53M FCF. Pivoting to branded GLP-1s (LLY/NVO) dodges compounding lawsuits, sets up higher-margin personalized care via diagnostics. At ~4x 2025 EV/sales (est.), dip buys into telehealth platform scaling.
Declining ARPU despite subscriber gains signals potential churn or pricing weakness in a GLP-1 market dominated by LLY/NVO, where HIMS lacks moat and faces branded pricing pressure eroding margins further.
"ARPU collapse (4% revenue growth on 9% subscriber growth) reveals margin deterioration that guidance doesn't adequately address, and the shift to reselling branded drugs signals HIMS is becoming a commoditized distribution layer, not a differentiated health platform."
HIMS missed EPS badly ($0.40 loss vs. $0.01 expected) and revenue ($608M vs. $616.5M), yet raised full-year guidance to $2.8–3B. The disconnect is critical: 9% subscriber growth paired with only 4% revenue growth signals collapsing ARPU (average revenue per user), likely from GLP-1 commoditization and price competition. Management's pivot to reselling branded drugs (Mounjaro, Wegovy) rather than proprietary formulations is a margin-compression tell. Free cash flow of $53M/quarter is real, but guidance to $200M annually assumes margin expansion that hasn't materialized. The stock deserves to fall.
If HIMS is successfully transitioning from high-margin proprietary GLP-1 to a diversified 'consumer health platform' model with lower per-unit margins but vastly larger TAM, the subscriber growth (9% YoY) could be the real leading indicator, and today's margin pain is temporary. Guidance raise despite miss suggests management confidence in execution.
"Hims & Hers's long-run platform expansion, diagnostics play, and GLP-1 resales could deliver outsized 2030 revenue growth and cash flow even if Q1 misses, setting up a potential multi-year re-rating."
Even with a Q1 miss, the stock drop may overstate near-term risk because the growth engine remains strong: 9% subscriber growth; guidance calls for $2.8-3.0B revenue this year and $6.5B by 2030; positive FCF of $53M in Q1 hints at underlying cash generation to fund expansion. The strategy to combine GLP-1 resale with diagnostics and new markets could lift LTV and margins over time, reducing reliance on a single product. However, the article glosses over margin dynamics, marketing costs, and regulatory risk around GLP-1, plus whether 2030 targets are credible given competition and potential policy shifts.
Q1 miss could signal that near-term costs of building the platform are higher than expected. If GLP-1 pricing or regulatory risk intensifies, the 2030 targets may prove unattainable.
"The pivot to branded drug distribution destroys the high-margin compounding moat, making the current valuation unsustainable."
Grok, your 4x EV/sales multiple is misleading because it ignores the quality of those earnings. HIMS is trading like a tech platform, but it operates like a low-moat pharmacy middleman. If they pivot to branded LLY/NVO drugs, they become a glorified distributor with zero pricing power. The real risk is the 'platform' thesis failing; if they can't maintain high-margin proprietary compounding, their CAC will eventually cannibalize all FCF, making that $6.5B 2030 target a pipe dream.
"HIMS subscriber growth is exposed to macroeconomic weakness in elective telehealth categories."
Panel, you're all zeroed in on GLP-1 ARPU/margins, missing macro vulnerability: HIMS core revenue (hair loss, ED, derm) is elective consumer spending, highly sensitive to recessions or rising unemployment. 9% sub growth crumbles if households trim 'nice-to-have' subscriptions. $53M FCF buys time, but $6.5B 2030 needs economic tailwinds nobody assumes. Cheap at 4x sales, but cyclical risk caps upside.
"GLP-1 commoditization is the near-term threat; recession is a secondary tail risk that doesn't explain Q1's ARPU collapse."
Grok flags real macro risk, but conflates two separate issues. Hair loss/ED are discretionary, yes—but GLP-1 is medical necessity for diabetics/obese patients, less cyclical. HIMS' Q1 miss wasn't driven by core elective categories tanking; it was ARPU compression within GLP-1 itself. The recession risk exists, but it doesn't explain the 9% sub growth paired with 4% revenue growth. That's a product-mix problem, not a macro one. Grok's cyclicality concern is valid for 2025+, but it's masking the immediate margin cliff.
"GLP-1 margin and regulatory risks threaten the 2030 target even if macro conditions improve."
Grok, your macro cyclicality point is valid, but the near-term danger is not a demand shock so much as a margin shock from GLP-1 mix. 9% subscriber growth with only 4% revenue implies ARPU erosion; even with platform cross-sell, hitting $6.5B by 2030 hinges on material margin expansion, not just topline. Any payer constraints, price pressure on branded GLP-1s, or tighter marketing rules could derail that path, regardless of macro.
The panel is divided on HIMS' future, with concerns about margin compression from shifting to branded drugs and potential ARPU erosion, but also optimism about subscriber growth and long-term guidance.
Strong subscriber growth and long-term revenue guidance.
Margin compression and ARPU erosion from shifting to branded drugs and potential product-mix issues.